Agonist
Back to library
MetabolicOral

5-Amino-1MQ

Also known as: 5-Amino-1-methylquinolinium · NNMT inhibitor

Small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is upregulated in obese adipose tissue and depletes the methyl donor SAM and NAD+ precursor NMN — inhibition restores cellular methylation capacity and may improve fat oxidation.

At a glance

Half-life
6 hours
Common route
Oral
Typical dose range
50,000–150,000mcg
Stability (reconstituted)
60days refrigerated

Best timing

Oral capsule once or twice daily with food. Effects on body composition appear over 8–12 weeks.

Contraindications

  • Pregnancy
  • Pediatric use
  • Limited long-term human safety data

Watch symptoms

  • Mild GI changes
  • Headache
  • Sleep changes (some users report vivid dreams)
  • Limited human trial data — pre-clinical only as of 2024

Citations

The primary literature.

  1. 01Nicotinamide N-methyltransferase knockdown protects against diet-induced obesityPubMed
  2. 02A small molecule inhibitor of nicotinamide N-methyltransferase reduces adiposity and metabolic dysfunction in obese micePubMed

Related protocols

Stacks that use 5-Amino-1MQ.

Metabolic Reset

Sixteen-week 5-Amino-1MQ plus low-dose GLP-1 for insulin sensitivity and metabolic flexibility.

View protocol
Back to library